Orthocell Ltd - Asset Resilience Ratio

Latest as of June 2025: 81.22%

Orthocell Ltd (OCC) has an Asset Resilience Ratio of 81.22% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Orthocell Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$28.62 Million
≈ $20.25 Million USD Cash + Short-term Investments

Total Assets

AU$35.24 Million
≈ $24.93 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Orthocell Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Orthocell Ltd.

Liquid Assets Composition Over Time

This chart breaks down Orthocell Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read OCC liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$28.62 Million 81.22%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$28.62 Million 81.22%

Asset Resilience Insights

  • Very High Liquidity: Orthocell Ltd maintains exceptional liquid asset reserves at 81.22% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Orthocell Ltd Industry Peers by Asset Resilience Ratio

Compare Orthocell Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Dianthus Therapeutics Inc.
NASDAQ:DNTH
Biotechnology 63.98%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 62.24%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%
Wecome Pharmaceutical Co Ltd
SHE:300878
Biotechnology 0.67%
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Biotechnology 86.66%
Relmada Therapeutics Inc
NASDAQ:RLMD
Biotechnology 95.25%
MediWound Ltd
F:M8W
Biotechnology 56.04%

Annual Asset Resilience Ratio for Orthocell Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Orthocell Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 75.20% AU$26.50 Million
≈ $18.75 Million
AU$35.24 Million
≈ $24.93 Million
-2.25pp
2024-06-30 77.45% AU$20.61 Million
≈ $14.59 Million
AU$26.62 Million
≈ $18.83 Million
-6.38pp
2023-06-30 83.83% AU$24.82 Million
≈ $17.56 Million
AU$29.61 Million
≈ $20.95 Million
+54.75pp
2022-06-30 29.08% AU$11.02 Million
≈ $7.80 Million
AU$37.90 Million
≈ $26.81 Million
-55.39pp
2021-06-30 84.47% AU$16.33 Million
≈ $11.55 Million
AU$19.33 Million
≈ $13.68 Million
-3.75pp
2020-06-30 88.22% AU$20.44 Million
≈ $14.46 Million
AU$23.17 Million
≈ $16.39 Million
+5.59pp
2019-06-30 82.63% AU$11.24 Million
≈ $7.95 Million
AU$13.60 Million
≈ $9.62 Million
+26.99pp
2018-06-30 55.65% AU$2.91 Million
≈ $2.06 Million
AU$5.23 Million
≈ $3.70 Million
-14.84pp
2017-06-30 70.49% AU$5.05 Million
≈ $3.57 Million
AU$7.16 Million
≈ $5.07 Million
--
pp = percentage points

About Orthocell Ltd

AU:OCC Australia Biotechnology
Market Cap
$132.46 Million
AU$187.20 Million AUD
Market Cap Rank
#18205 Global
#553 in Australia
Share Price
AU$0.69
Change (1 day)
-0.72%
52-Week Range
AU$0.69 - AU$1.53
All Time High
AU$1.75
About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more